Comparative Pharmacology
Head-to-head clinical analysis: METADATE CD versus METHYLPHENIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METADATE CD versus METHYLPHENIDATE.
METADATE CD vs METHYLPHENIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
20-60 mg orally once daily in the morning
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
None Documented
None Documented
Clinical Note
moderateDexmethylphenidate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexmethylphenidate."
Clinical Note
moderateBretylium + Methylphenidate
"Bretylium may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateCyamemazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate."
Clinical Note
moderateSulpiride + Methylphenidate
Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2%
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
Category C
Category A/B
CNS Stimulant
CNS Stimulant
"The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate."